Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae
Copyright © 2017 American Society for Microbiology..
In vivo induction of AmpC beta-lactamases produces high-level resistance to many beta-lactam antibiotics in Enterobacteriaceae, often resulting in the need to use carbapenems or cefepime (FEP). The clinical effectiveness of piperacillin-tazobactam (TZP), a weak inducer of AmpC beta-lactamases, is poorly understood. Here, we conducted a case-control study of adult inpatients with bloodstream infections (BSIs) due to Enterobacter, Serratia, or Citrobacter species from 2009 to 2015 to assess outcomes following treatment with TZP compared to FEP or meropenem (MEM). We collected clinical data and screened all isolates for the presence of ampC alleles by PCR. Primary study outcomes were 30-day mortality and persistent bacteremia at ≥72 h from the time of treatment initiation. Of 493 patients with bacteremia, 165 patients met the inclusion criteria, of which 88 were treated with TZP and 77 with FEP or MEM. To minimize differences between covariates, we carried out propensity score matching, which yielded 41 matched pairs. Groups only differed by age, with patients in the TZP group significantly older (P = 0.012). There were no significant differences in 30-day mortality, persistent bacteremia, 7-day mortality, or treatment escalation between the two treatment groups, including in the propensity score-matched cohort. PCR amplification and sequencing of ampC genes revealed the presence of ampC in isolates with cefoxitin MICs below 16 μg/ml, in particular in Serratia spp., and demonstrated that these alleles were highly genetically diverse. Taken together, TZP may be a valuable treatment option for BSIs due to AmpC beta-lactamase-producing Enterobacteriaceae, diminishing the need for broader-spectrum agents. Future studies are needed to validate these findings.
| Errataetall: |
CommentIn: Antimicrob Agents Chemother. 2017 Aug 24;61(9):. - PMID 28839082 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Antimicrobial agents and chemotherapy - 61(2017), 6 vom: 15. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cheng, Lucy [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.03.2018 Date Revised 02.12.2018 published: Electronic-Print CommentIn: Antimicrob Agents Chemother. 2017 Aug 24;61(9):. - PMID 28839082 Citation Status MEDLINE |
|---|
| doi: |
10.1128/AAC.00276-17 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM270103929 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM270103929 | ||
| 003 | DE-627 | ||
| 005 | 20231224225834.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/AAC.00276-17 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0900.xml |
| 035 | |a (DE-627)NLM270103929 | ||
| 035 | |a (NLM)28320724 | ||
| 035 | |a (PII)e00276-17 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cheng, Lucy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.03.2018 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a CommentIn: Antimicrob Agents Chemother. 2017 Aug 24;61(9):. - PMID 28839082 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 American Society for Microbiology. | ||
| 520 | |a In vivo induction of AmpC beta-lactamases produces high-level resistance to many beta-lactam antibiotics in Enterobacteriaceae, often resulting in the need to use carbapenems or cefepime (FEP). The clinical effectiveness of piperacillin-tazobactam (TZP), a weak inducer of AmpC beta-lactamases, is poorly understood. Here, we conducted a case-control study of adult inpatients with bloodstream infections (BSIs) due to Enterobacter, Serratia, or Citrobacter species from 2009 to 2015 to assess outcomes following treatment with TZP compared to FEP or meropenem (MEM). We collected clinical data and screened all isolates for the presence of ampC alleles by PCR. Primary study outcomes were 30-day mortality and persistent bacteremia at ≥72 h from the time of treatment initiation. Of 493 patients with bacteremia, 165 patients met the inclusion criteria, of which 88 were treated with TZP and 77 with FEP or MEM. To minimize differences between covariates, we carried out propensity score matching, which yielded 41 matched pairs. Groups only differed by age, with patients in the TZP group significantly older (P = 0.012). There were no significant differences in 30-day mortality, persistent bacteremia, 7-day mortality, or treatment escalation between the two treatment groups, including in the propensity score-matched cohort. PCR amplification and sequencing of ampC genes revealed the presence of ampC in isolates with cefoxitin MICs below 16 μg/ml, in particular in Serratia spp., and demonstrated that these alleles were highly genetically diverse. Taken together, TZP may be a valuable treatment option for BSIs due to AmpC beta-lactamase-producing Enterobacteriaceae, diminishing the need for broader-spectrum agents. Future studies are needed to validate these findings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a AmpC beta-lactamases | |
| 650 | 4 | |a bacteremia | |
| 650 | 4 | |a piperacillin-tazobactam | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a Piperacillin, Tazobactam Drug Combination |2 NLM | |
| 650 | 7 | |a 157044-21-8 |2 NLM | |
| 650 | 7 | |a Penicillanic Acid |2 NLM | |
| 650 | 7 | |a 87-53-6 |2 NLM | |
| 650 | 7 | |a AmpC beta-lactamases |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 650 | 7 | |a beta-Lactamases |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 650 | 7 | |a Piperacillin |2 NLM | |
| 650 | 7 | |a X00B0D5O0E |2 NLM | |
| 700 | 1 | |a Nelson, Brian C |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Seval, Nikhil |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Giddins, Marla J |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Qiuhu |e verfasserin |4 aut | |
| 700 | 1 | |a Whittier, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Gomez-Simmonds, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Uhlemann, Anne-Catrin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antimicrobial agents and chemotherapy |d 1972 |g 61(2017), 6 vom: 15. Juni |w (DE-627)NLM000026506 |x 1098-6596 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2017 |g number:6 |g day:15 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/AAC.00276-17 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 61 |j 2017 |e 6 |b 15 |c 06 | ||